Albert Erani Biography and Net Worth

Major Shareholder of Organogenesis


Albert Erani serves as Independent Director of the Company. Mr. Erani co-founded A & E Stores, Inc. and has served as its Vice President, Principal and Secretary since 1971. Mr. Erani is Principal of Rugby Realty Co., Inc., an entity that owns real estate partnerships. Mr. Erani is the first cousin of Alan Ades.

What is Albert Erani's net worth?

The estimated net worth of Albert Erani is at least $168.81 million as of January 9th, 2024. Mr. Erani owns 59,025,106 shares of Organogenesis stock worth more than $168,811,803 as of April 16th. This net worth approximation does not reflect any other assets that Mr. Erani may own. Learn More about Albert Erani's net worth.

How do I contact Albert Erani?

The corporate mailing address for Mr. Erani and other Organogenesis executives is 85 Dan Road, Canton MA, 02021. Organogenesis can also be reached via phone at (781) 575-0775 and via email at [email protected]. Learn More on Albert Erani's contact information.

Has Albert Erani been buying or selling shares of Organogenesis?

Albert Erani has not been actively trading shares of Organogenesis during the last ninety days. Most recently, Albert Erani sold 197,921 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a transaction totalling $864,914.77. Following the completion of the sale, the insider now directly owns 59,025,106 shares of the company's stock, valued at $257,939,713.22. Learn More on Albert Erani's trading history.

Who are Organogenesis' active insiders?

Organogenesis' insider roster includes Albert Erani (Major Shareholder), Dennis Erani (Major Shareholder), Gary Gillheeney (CEO), Michael Katz (Major Shareholder), and Glenn Nussdorf (Director). Learn More on Organogenesis' active insiders.

Are insiders buying or selling shares of Organogenesis?

In the last twelve months, insiders at the sold shares 1 times. They sold a total of 197,921 shares worth more than $864,914.77. The most recent insider tranaction occured on January, 9th when Major Shareholder Albert Erani sold 197,921 shares worth more than $864,914.77. Insiders at Organogenesis own 34.0% of the company. Learn More about insider trades at Organogenesis.

Information on this page was last updated on 1/9/2024.

Albert Erani Insider Trading History at Organogenesis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Sell197,921$4.37$864,914.7759,025,106View SEC Filing Icon  
4/12/2023Sell25,000$2.07$51,750.0059,223,027View SEC Filing Icon  
6/13/2022Sell29,669$4.89$145,081.4159,248,027View SEC Filing Icon  
6/8/2022Sell20,000$5.39$107,800.0059,278,027View SEC Filing Icon  
6/6/2022Sell100,000$5.41$541,000.0059,348,027View SEC Filing Icon  
6/9/2021Sell150,000$15.31$2,296,500.00View SEC Filing Icon  
6/7/2021Sell94,612$16.14$1,527,037.68View SEC Filing Icon  
6/4/2021Sell60,000$16.22$973,200.00View SEC Filing Icon  
See Full Table

Albert Erani Buying and Selling Activity at Organogenesis

This chart shows Albert Erani's buying and selling at Organogenesis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Organogenesis Company Overview

Organogenesis logo
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Today's Range

Now: $2.86
Low: $2.75
High: $2.90

50 Day Range

MA: $3.09
Low: $2.61
High: $3.84

2 Week Range

Now: $2.86
Low: $1.79
High: $4.70

Volume

950,423 shs

Average Volume

761,933 shs

Market Capitalization

$377.41 million

P/E Ratio

71.52

Dividend Yield

N/A

Beta

1.57